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Background: Area-level variation in treatment and outcomes may be a potential source of confounding bias in
observational comparative effectiveness studies. This paper demonstrates how to use exploratory spatial data analysis
(ESDA) and spatial statistical methods to investigate and control for these potential biases. The case presented
compares the effectiveness of two antipsychotic treatment strategies: oral second-generation antipsychotics (SGAs) vs.
long-acting paliperiodone palmitate (PP).
Methods: A new-start cohort study was conducted analyzing patient-level administrative claims data (8/1/2008–4/30/
2011) from Missouri Medicaid. ESDA techniques were used to examine spatial patterns of antipsychotic prescriptions
and outcomes (hospitalization and emergency department (ED) visits). Likelihood of mental health-related outcomes
were compared between patients starting PP (N = 295) and oral SGAs (N = 8,626) using multilevel logistic regression
models adjusting for patient composition (demographic and clinical factors) and geographic region.
Results: ESDA indicated significant spatial variation in antipsychotic prescription patterns and moderate variation in
hospitalization and ED visits thereby indicating possible confounding by geography. In the multilevel models for this
antipsychotic case example, patient composition represented a stronger source of confounding than geographic
context.
Conclusion: Because geographic variation in health care delivery is ubiquitous, it could be a comparative
effectiveness research (CER) best practice to test for possible geographic confounding in observational data.
Though the magnitude of the area-level geography effects were small in this case, they were still statistically
significant and should therefore be examined as part of this observational CER study. More research is needed to
better estimate the range of confounding due to geography across different types of observational comparative
effectiveness studies and healthcare utilization outcomes.
Keywords: Comparative effectiveness research, Antipsychotics, Mental health, Small area variation, Geographic
information systems, Spatial data analysis, Multilevel modelingBackground
Tremendous progress in codifying best practices for con-
ducting comparative effectiveness research (CER) using
observational datasets has been made. The Agency for
Healthcare Research and Quality (AHRQ) [1] and Patient
Centered Outcomes Research Institute (PCORI) [2] have
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unless otherwise stated.design and implementation of CER studies. These reports
stress that observational CER studies require multidimen-
sional analytic strategies and careful consideration of
which multivariate modeling approaches best represent
the structure of the data, the study outcome, and expos-
ure/treatment being studied. What is largely absent from
the CER literature is an explicit discussion of how geo-
graphical context can affect observational studies and, in
particular, introduce bias into statistical analyses (see, for
example, the August 2013 special supplement on methods
for CER/PCOR in the Journal of Clinical Epidemiology).d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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patterns, and the availability and accessibility of hospital,
specialty, and primary care can influence both treatment
choices and care seeking behaviors [3-6]. These differ-
ences may, in turn, be reflected in health-care utilization
databases often used in CER studies [7]. Spatial statistical
methods, which examine small-area variation in these fac-
tors, can provide additional information to assist in fur-
ther alleviating bias in observational CER studies.
The Dartmouth Atlas of Healthcare series [8-10] and
the Atlas of U.S. Mortality [11] provide strong empirical
evidence of geographical patterns of mortality, disease,
health care resource availability and service utilization
across the U.S. Since their publication in the mid-1990’s,
numerous studies have demonstrated geographical dif-
ferences in health and health care for many outcomes
and procedures. This literature suggests that two geo-
graphic principles govern spatial patterns of care. First,
people with similar demographic characteristics and risk
factors tend to live near each other, producing larger
areal patterns of morbidity and mortality [12]. This is
often referred to as the compositional effect, since the
geographic patterns are due to the underling compos-
ition of the population. These patterns, for a variety of
socio-demographic reasons, often translate to variations
in service use, particularly hospitalization and emergency
department (ED) visits. For example, a county with more
low income individuals may exhibit higher rates of ED
visits for asthma because the condition is not being
managed well due to lack of primary care. These pat-
terns are particularly important for observational CER
studies, which rely on electronic medical records, insur-
ance claims or hospital discharge data to measure out-
comes. Many of the analytic strategies suggested by
AHRQ and PCORI attempt to account for this variation
by controlling for, (e.g., multivariate models) or match-
ing on (e.g., propensity scores), patient-level characteris-
tics. If the area-level differences are indeed due to
compositional effects, these techniques should be effect-
ive in controlling for bias.
The second geographic principle which drives spatial
patterns of morbidity and utilization is the notion of areal
contextual differences. The care a person receives depends
upon the supply of resources available and physician prac-
tice patterns in the place the person lives [13]. Recent CER
work has introduced instrumental variables (IVs) to cap-
ture geographic variation in practice patterns which may
affect treatment exposure [14-16]. Unfortunately, one con-
dition of an IV is that it: “is a cause of treatment but has
no causal association with the outcome other than through
its effect on treatment” [1], which is difficult for many CER
studies. The social epidemiology and sociology literature
also suggests that health outcomes, service utilization and
treatment decisions are affected by social and culturalnorms, social ties and neighborhood disorganization, often
measured using area-level socioeconomic status [17-21].
The current literature on geographic variation in health
has shifted from descriptive analysis of spatial patterns to
sophisticated statistical analyses of the contextual factors
which contribute to these patterns [22-26]. Contextual fac-
tors are ubiquitous in social epidemiological analyses but
rarely considered in CER. IVs cannot be used to control for
area-level socio-economic or cultural patterns because
these variables are often highly related to the outcome
under study. As such, there is a need to integrate valuable
knowledge from geography, social epidemiology and soci-
ology into CER best practices in order to explore the effect
of geographical variations in area-level socioeconomic sta-
tus (SES) and utilization on both the treatment exposure
and the outcome under study.
In this study, we seek to build upon the strong analytic
foundation laid by AHRQ and PCORI by suggesting that
exploratory spatial data analysis (ESDA) and spatial stat-
istical methods be integrated into CER studies and in-
cluded in guidelines for rigorous CER methods. This
study is based on two hypotheses related to two poten-
tial sources of confounding bias: 1) drug prescription
patterns (our study exposure) may vary geographically
as adoption may be uneven throughout the state, and
2) hospitalization and ED visits (our study outcomes)
may vary geographically depending upon local referral
and treatment practices and availability of health services
(e.g., in urban vs. rural areas). Therefore, we investigate
whether area-level geographic variation in treatment and
outcomes is a source of confounding bias in this observa-
tional comparative effectiveness study. ESDA is a powerful
tool which can be used to understand the potential biases
produced by area-level compositional and contextual
factors in CER studies, while spatial statistical methods
can control for these biases. We demonstrate these
techniques, and their utility, with a case study that
compares the effectiveness of paliperidone palmitate, a
long-acting second-generation antipsychotic (SGA), with
orally-administered SGA’s among Medicaid patients in the
State of Missouri. If area-level variation is a source of con-
founding bias, it should be investigated as part of good
comparative effectiveness research practices.
Methods
This is a secondary analysis of a retrospective observa-
tional study using a new user cohort design. Although we
have examined these data using other methods appropri-
ate for observational data (e.g., propensity score matching
and provider and patient restricted cohorts), we do not
present these analyses here. Rather, we focus on additional
geographic analyses not typically included in observational
CER studies which aim to determine how geographical
differences in the treatment and outcome may affect
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utilization, and hospitalization/ED visit rates, 2) smooth-
ing those rates using Spatial Empirical Bayes (SEB) meth-
odologies, and 3) analyzing spatial patterns using Moran’s
I and local indicators of spatial association to look for local
clustering. Second, we developed multilevel logistic re-
gression models and mapped random effects to evaluate
model performance and the effect of spatial differences in
utilization and admission rates on the interpretation of
our results.
This study received approval from the University of
Colorado Denver Multiple Institutional Review Board
(IRB) and adhered to Data Use Agreements specified by
the State of Missouri.
Data
Patient-level data were extracted from Missouri MOHealth-
Net (Medicaid) and Department of Mental Health adminis-
trative databases (see Additional file 1: Figure S1 for
CONSORT diagram of study population). Medicaid clients
with a prescription claim for paliperidone palmitate or an
oral SGA agent between August 1, 2009 and April 30,
2010 (inclusive) were identified. Oral SGAs studied were
aripiprazole, asenapine, clozapine, iloperidone, lurasidone,
olanzapine, quetiapine, risperidone, and ziprasidone. Pali-
peridone palmitate received FDA approval July 2009, de-
fining the beginning of patient accrual. The most current
data available at the time the investigation began (April
30, 2011) was used to define the end of 12-month follow-
up observation. Medicaid clients who were Medicare
eligible or had Medicaid eligibility less than 12 months
before and after the first qualifying pharmacy (Index)
claim date were excluded because claims data or obser-
vation follow-up would be incomplete. The primary
analysis compared outcomes in the New Start Cohorts
of paliperidone palmitate (N = 296) and oral SGA (N =
8,675) users.
Mental-health related hospitalization and ED visits in
the year post drug initiation were the primary outcomes
studied. An outcome was defined as mental health re-
lated if the first diagnosis of the claim record was for a
mental disorder specified in the AHRQ Mental Health
and Substance Abuse Classification [27].
Several baseline (past year) demographic and clinical
characteristics were identified as possible confounders.
Demographic characteristics included: age, sex, and race.
Other patient characteristics included: mental health con-
ditions (identified using ICD-9-CM diagnosis codes), car-
diometabolic co-morbidities (diabetes, disorders of lipid
metabolism, hypertension, and diseases of the heart, iden-
tified using ICD-9-CM codes), frequency of hospitaliza-
tions and outpatient visits, receipt of care at a Community
Mental Health Center (CMHC), and evidence of case
management. Information on the patient and clinicalfactors used to adjust models is available from prior pub-
lished studies [28,29].
Geographic location of the patient was identified using
both county and 5-digit zip code of residence. Zip codes
were used to categorize patients into state-defined men-
tal health service areas (MHSA). Fifty records were lost
due to the inability to assign a geographic location, redu-
cing the sample to 8,921. Study participants were nested
into 115 counties (114 counties and 1 independent city)
and 27 MHSAs.
Statistical analysis
Spatial empirical bayes smoothing
Rate smoothing is a technique used to: 1) stabilize rates
based on small numbers and 2) reduce noise in rates
caused by different population sizes [30,31]. In the context
of CER, especially with new drug introductions where
study populations are smaller, rate smoothing allows us to
examine data at a finer spatial resolution (e.g., zip codes)
rather than aggregating data to larger regions (e.g., coun-
ties). Rate smoothing increases the ability to discern sys-
tematic patterns in the spatial variation of the outcome
under study by reducing noise and making trends and pat-
terns more obvious.
Spatial Empirical Bayes (SEB) smoothing was used to
create rate maps of paliperidone palmitate and oral SGA
utilization and hospitalization and ED visits. SEB averages
the rate in each zip code with the rates from neighboring
zip codes. SEB smoothing “borrows” data on events from
nearby regions (“neighbors”) to stabilize local estimates by
weighting the rate based on those neighboring values [32].
For all spatial analyses in this study, neighbors are defined
using queen’s case continuity, which creates links between
all neighbors sharing a common point on their boundar-
ies. This smoothing method is commonly used with data
that is already aggregated to areas, because it uses con-
tiguity to define neighbors. Other methods, such as kernel
density smoothing are often typically used, but more often
with point-level data where distance between individual
events can be measured precisely.
Moran’s I and LISA
Smoothed rate maps do not indicate if observable spatial
patterns are statistically significant. Moran’s I and local
indicators of spatial association (LISA) are two explora-
tory statistical techniques which test whether or not
rates cluster in space and highlight the location of local
pockets of mutually similar deviations from the overall
mean regional rate.
The Moran's I statistic measures global clustering or,
more formally, spatial autocorrelation among rates across
all zip codes in the study area [33]. Moran's I is a weighted
correlation coefficient, similar to Pearson’s correlation co-
efficient, where weights are based on spatial proximity of
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large positive or negative Moran’s I indicates utilization or
admission rates in nearby areas are highly similar (or dis-
similar), whereas when Moran's I near 0 indicates no
spatial association in the data.
Moran's I is a global test and does not indicate where
clusters are located in the study area. The LISA was there-
fore used as an indicator of local spatial association [34].
The LISA measures whether, for each zip code, the
utilization or admission rate is closer to the values of its
neighbors or to the state average. Significance was
assessed using Monte Carlo simulations with 999 permu-
tations. LISA results were then mapped. Significant spatial
associations are designated as: 1) ‘high–high’ which indi-
cates that high rates are next to each other (positive spatialFigure 1 Spatial Distribution of Drug Utilization Rates for A) Paliperid
Maps and Global Moran’s I Value for C) Paliperidone Palmitate and D
Empirical Bayes (SEB) smoothing methods. All maps were developed by ag
of the MHSAs and light grey lines indicate county boundaries.autocorrelation), 2) ‘low–high’ indicates that low rates are
adjacent to high rates (negative spatial autocorrelation), 3)
‘low–low’ indicates clustering of low rates (positive spatial
autocorrelation), 4) ‘high–low’ indicates that high rates are
adjacent to low rates (negative spatial autocorrelation), or
5) ‘not significant’ indicates that there is no spatial auto-
correlation. SEB rates, Moran’s I and LISA statistics were
calculated using OpenGeoDa v1.0.1 and R v2.13.0.
Multilevel modeling
After examining the results of the ESDA, we hypothesized
spatial patterns of drug utilization and outcomes were
clustered within both counties and MHSA. Multilevel lo-
gistic regression models where patients were nested within
either counties or MHSAs [35,36] were performed toone Palmitate and B) Oral SGAs with Corresponding LISA Cluster
) Oral SGAs. Note: Maps A and B were developed using Spatial
gregating data to zip codes. Dark black lines indicate the boundaries
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idone palmitate vs. oral SGA and the likelihood of a men-
tal health hospitalization or ED visit. To determine the
extent to which counties/MHSAs were independently as-
sociated with outcomes, we used a random intercept
model (unadjusted models) to partition the variance be-
tween MHSAs and patient-level characteristics. Individual
level characteristics (adjusted models) were then added as
fixed effects to the model and finally MHSA- or county-
level random effects (adjusted random effects models)
were included. We used a spatially structured level-2 error
term in order to control for potential spatial autocorrel-
ation. Covariance matrices were based on an exponential
distance decay function of the form σ2exp{−dij/θ}, such
that zip codes close to one another would have a largerFigure 2 Spatial Distribution of A) Primary Mental Health Hospitalizat
LISA Cluster Maps and Global Moran’s I Value for C) Hospitalizations
Empirical Bayes (SEB) smoothing methods. All maps were developed by ag
of the MHSAs and light grey lines indicate county boundaries.covariance estimate than those further apart. As a robust-
ness check, both spatially structured and non-spatially
structured random effect models were examined, and esti-
mates were nearly identical. We chose to present the
spatially structured error terms because we believe they
were more theoretically grounded.
Several iterations of the models were run including:
intercept-only random effects, slope-only random ef-
fects and both intercept and slope random effects. The
intercept-only models were chosen as the “best model”
based on model fit statistics and significance tests of
the random effects. The intra-class correlation (ICC),
which is the ratio of the between group variance to the
total variance, was calculated to estimate the percent of
variance in the outcome that is between MHSAs orions and B) Primary Mental Health ED Visits with Corresponding
and D) ED Visits. Note: Maps A and B were developed using Spatial
gregating data to zip codes. Dark black lines indicate the boundaries
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to examine where the probability of a hospitalization or
ED visit deviated significantly from the global mean after
controlling for individual-level factors. Regression models
were run using the GLIMMIX procedure in SAS v9.3. No
adjustment was made for multiplicity.
Results and discussion
Figures 1 and 2 present results of the exploratory spatial
data analyses for drug utilization rates (Figure 1) and
hospitalization and ED visit rates (Figure 2). Figure 1A and
B show the SEB smoothed rates for paliperidone palmitate
and oral SGAs. Results indicate a clear spatial pattern of
oral SGA use in the southern part of Missouri, which is
predominantly rural with small towns and sparse popula-
tion. Qualitatively, paliperidone palmitate utilization rates
were higher in the southeast corner and north central por-
tion of the state relative to other regions. Utilization of
both drugs was higher in the major metropolitan areas of
St. Louis and Kansas City. Figure 1C and D show the re-
sults of the Moran’s I and LISA analyses. The Moran’s I in-
dicates that there is statistically significant, but weak,
clustering of paliperidone palmitate (I = 0.05; p = 0.004)
and a stronger clustering effect of oral SGAs (I = 0.16, p <
0.0001). The LISA maps indicate paliperidone palmitate
had no strong visual pattern of local clustering (which is
also reflected in the low Moran’s I of 0.05), but oral SGAs
exhibited clusters of high use in the southeast corner, and
a cluster of low utilization to the north of Kansas City and
around St. Louis (which is reflected in a higher Moran’s I
of 0.16).
Figure 2A and B show the SEB smoothed rates for ED
visits and hospitalizations. Results indicate no clear spatialFigure 3 Likelihood of mental-health related hospitalizations and em
compare patients starting paliperidone palmitate to patients starting oral seco
(paliperidone palmitate or oral SGA), patient demographics (age, sex, race), sc
baseline psychotropic drug use, health care utilization (case management, ou
mental-health hospitalizations or mental-health ED visits in the baseline periopattern for ED visits and hint at slightly higher hospitaliza-
tions in the southern portion of the state. The Moran’s I
and LISA results strengthen this conclusion in Figure 2C
and D. The Moran’s I is not statistically significant for ED
visits, though LISA maps indicate the ED visits are high in
the city cores of both Kansas City and St. Louis. The Mor-
an’s I for hospitalizations is weak and borderline signifi-
cant (I = 0.03; p = 0.05), and the LISA map indicates
several larger clusters of high hospitalization in the south-
east corner, and clusters of low rates in the northern re-
gion of the state.
Taken together, these results indicate that treatment ex-
posure varied across regions, qualitatively indicated by vis-
ual interpretation of spatial patterns and quantitatively
confirmed by statistically significant Moran’s I and LISA
values, and that moderate spatial differences in the out-
comes used to examine the effectiveness of paliperidone
palmitate exist. The maps also qualitatively suggest
both county-level and MHSA-level patterns exist for
drug utilization.
Additional file 1: Table S1 shows the baseline charac-
teristics of patients starting paliperidone palmitate and
oral SGAs. Figure 3 shows the results of the unadjusted
and adjusted regression models for: a) no random effects
(RE), b) MHSA-level random effects, and c) county-level
random effects. After adjustment, the point estimates
shifted in the direction of a protective benefit for per-
sons initiating paliperidone palmitate compared to an
oral SGA. The adjusted odds ratio (AOR) for hospitali-
zations was 0.80 (95% CI: 0.59-1.10) and for ED visits
was 0.76 (95% CI: 0.56-1.04). Adding MHSA- or county-
level random effects moved point estimates slightly to-
ward the null, indicating that individual-level covariatesergency department visits after drug initiation. Odds ratios
nd-generation antipsychotics. Adjusted models adjust for: cohort
hizophrenia, baseline mental health and cardiometabolic co-morbidities,
tpatient visits), antipsychotic medication adherence, and frequency of
d.
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case. The difference between MHSA- and county-level
random effects on model results is negligible, suggesting
either could be used as a level-2 unit in this analysis.
Additional file 1: Tables S2 and S3 present results for these
models as well as additional models which included slope-
only and intercept and slope random effects.
Figure 4 maps the random effects, or deviations from
the overall model mean value. P-values indicate if the
random effect is significantly different from the mean.
Figure 4A and B show county-level and MHSA-level
random effects for mental health hospitalizations and in-
dicate one county/MHSA just outside St. Louis where
the likelihood of hospitalization is significantly higherFigure 4 Spatial Distribution of Random Effects for Adjusted Multivar
county, B) Primary Mental Health Hospitalizations for the MHSA, C) P
Mental Health ED Visits for the MHSA. Note: Values mapped are the est
or ED visit derived from the regression model. P-values indicate areas wher
Values are classed using standard deviations in order to make them compathan the study area as a whole. Figure 4C and D show
random effects for mental health ED visits and indicate
a high likelihood of a visit in the same region as well as
in St. Louis.
Table 1 shows the variance components estimated from
the multi-level models. Overall, about 1% of the variance
in hospitalizations and 2% of the variance in ED visits is ex-
plained by county or MHSA differences. After adjusting
for patient-level factors, this variance is approximately
halved, suggesting that underlying population composition
factors explain much of the variation across regions. How-
ever, since the random effects for adjusted models are sta-
tistically significant, there are still area-level contextual
factors that are responsible for variation across regions.iate models for A) Primary Mental Health Hospitalizations for the
rimary Mental Health ED Visits for the county and D) Primary
imated deviations from the global mean probability of a hospitalization
e the random effect was significantly different from the model mean.
rable across models.
Table 1 Variance Components and Intra-class Correlation
(ICC) for Random Effects Models
Var SE p-value ICC
Mental-health Related Hospitalizations
Unadjusted, MHSA Random Effect 0.034 0.017 <0.0001 1.0%
Adjusted, MHSA Random Effect 0.017 0.014 0.033 0.5%
Unadjusted, County Random Effect 0.044 0.020 <0.0001 1.3%
Adjusted, County Random Effect 0.023 0.018 0.029 0.7%
Mental-health Related ED Visits
Unadjusted, MHSA Random Effect 0.071 0.027 <0.0001 2.1%
Adjusted, MHSA Random Effect 0.027 0.016 0.001 0.8%
Unadjusted, County Random Effect 0.070 0.023 <0.0001 2.1%
Adjusted, County Random Effect 0.037 0.019 0.001 1.1%
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Other studies have also suggested that geographic vari-
ation in treatments and outcomes can affect CER studies
using observational data [7]. Our ESDA results indicated
that geographic differences in treatment exposure (drug
utilization) and outcomes (mental health hospitalizations
and ED visits) are a potential confounder in this compara-
tive effectiveness study of antipsychotics in the Missouri
Medicaid system. Therefore, geography was incorporated
into the multilevel models. The multilevel models indi-
cated that adjusting for individual-level (compositional)
factors explained about half the variation in outcomes evi-
dent across counties and MHSAs. This means that un-
measured compositional or additional contextual factors
are possibly responsible for variation, for example as
shown in the significant random effects in the St. Louis
area. If there is sufficient sample, the recommended next
step in a CER study would be to include area-level predic-
tors (such as poverty rates or information on provider net-
works or practice patterns) in the level-2 portion of the
multilevel model to better understand (and control for)
the area-level contextual effects that drive these differ-
ences in outcomes. Due to our small sample size there
was insufficient level-2 variance left after adding
individual-level variables to continue with this analysis. In
this case example, comparing the effectiveness of anti-
psychotic treatments, patient-level compositional factors
were the most important driver of geographic variation.
Similar results have been found in a variety of studies
across public health disciplines; with many researchers
agreeing that area-level characteristics only explain a mod-
est amount of the variation in individual-level outcomes,
perhaps in the order of 5-10% [37-39]. More research is
needed to better estimate the range of confounding due to
geography in observational comparative effectiveness
studies and healthcare utilization outcomes. Exploratory
spatial data analysis offers a suite of geographic tools that
can be used to examine the potential confounding effectof geographical differences in the treatment and outcome
being studied in observational CER studies. The results
from ESDA can be used to examine whether geographic
clustering conforms to specific geographic boundaries and
can inform the choice of the level-2 unit for multilevel re-
gression analyses. In the current study, the SEB rate maps
indicated both county-level and MHSA-level patterns of
hospitalization.
We suggest the PCORI and AHRQ guidelines could in-
clude ESDA and spatial statistical methods as additional
techniques useful for statistical analyses of observational
CER. In particular, the section describing descriptive sta-
tistics and unadjusted analyses could include a discussion
of ESDA techniques and the section on adjusted analyses
could discuss the use of area-level random effects and
area-level predictors within multi-level model frameworks.
The PCORI and AHRQ guidelines set high standards for
the quality of CER studies and the inclusion of geographic
methods will only serve to strengthen these guidelines.
Not every study needs to adjust for geospatial variation,
but we suggest it should be a CER best practice to test for
possible geographic confounding. As most observational
datasets commonly used for CER record some type of
geographic indicator (e.g., zip code, county, address), con-
ducting geographic analyses should become ubiquitous.
Beyond the utility and importance of the ESDA and
spatial statistical analyses presented here, geographically
explicit results can assist with the translation of research
into practice. State and private health care delivery sys-
tems are often geographically defined. Policy makers seek
to understand where people who need care are located
and whether there are sufficient resources in a given re-
gion to support that population. Mapping results, as we
do in this study, naturally informs the way in which policy
makers intuitively examine the health system. They help
to answer questions like: What resources need to be
placed where? Which regions of the state have popula-
tions that might benefit from introduction of a new drug?
Maps and geographic analyses provide valuable tools for
hypothesis building and guiding policy decisions.
Study limitations should be acknowledged. First, al-
though many covariates were included in the multivariable
modeling, there may be omitted (or unmeasured) factors
that are important to the comparisons being made. In
addition, because this is an observational comparative ef-
fectiveness study in which treatment was not randomized,
observed statistical associations do not necessarily mean
there is a causal relationship. Therefore, effect estimates
should be cautiously interpreted. With regard to this par-
ticular comparison, paliperidone palmitate was a newly
launched drug at the time of the analysis and the sample
size was limited which hindered our ability to find statis-
tical significance. This is particularly problematic for
mixed-effect models because small sample sizes within
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random effects estimates. With a larger cohort, we could
conduct additional model adjustment, such as propensity
score matching or other restricted cohort methods, and
then use multi-level models on the matched/restricted co-
hort. In addition, county- or MHSA-level fixed effects
could be used to determine the contextual effects driving
significant level-2 random effects. Second, this analysis
provides a snapshot in time (one year of new starts) and
selection bias and utilization rates may change over time
as new drugs are adopted. Future analyses should consider
multiple time points in order to examine how results of
CER change over time as the new drug is incorporated in
to the health system.
In summary, because geographic variation in health
care delivery is ubiquitous, unmeasured confounding
due to geography may be present in observational CER
studies. Because measures of geographic location are
commonly available in electronic medical records and
administrative claims databases, we argue that CER best
practices should include examination of possible geo-
graphic confounding in observational data. This paper il-
lustrated methods for conducting such an examination.Additional file
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three supplementary tables for the manuscript. The Figure S1.
shows the inclusion/exclusion criteria for the study population, Table S1.
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